Fig. 7.

Inhibition of tumour growth by the LPPC/RBDV-IgG1 Fc plasmid/RBDV-IgG1 Fc protein. a Female C57BL/6 mice (6–8 weeks of age) were subcutaneously inoculated with 1 × 10⁶ cells in 100 mL of PBS. When the average tumour volume reached 30 mm³, the mice were i.v. injected with LPPC/RBDV-IgG1 Fc plasmid/RBDV-IgG1 Fc protein or other groups and injected again after four days. Inverted filled triangle means the day of complex injection. Tumour volume was measured every 2 days after injecting the complexes, and the mice were sacrificed when the tumour grew to a size of 2500 mm³. The data represent the mean tumour volume ± SD (n = 7). b The survival rate of C57BL/6 mice bearing B16-F10 tumours treated with LPPC/RBDV-IgG1 Fc plasmid/RBDV-IgG1 Fc protein or other groups. LPPC, which encapsulated with RBDV or IgG1 Fc, were all complexed by PEG